<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="22">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00727259</url>
  </required_header>
  <id_info>
    <org_study_id>P04067</org_study_id>
    <nct_id>NCT00727259</nct_id>
  </id_info>
  <brief_title>Evaluation of Satisfaction in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C (Study P04067)</brief_title>
  <acronym>SATISFACTION</acronym>
  <official_title>Evaluation of Satisfaction in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>France: Not Applicable</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current gold standard for treatment of chronic hepatitis C (CHC) patients is with
      pegylated interferon plus ribavirin. Drug administration accuracy and ease of use will
      definitely determine treatment effectiveness. This is the idea behind the development and
      usage of the PegPen. The goal of this study is to determine the satisfaction grade with this
      novel device.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Enrollment of patients will occur in a sequential order of treatment initiation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Evaluation of the Satisfaction of the PegPen (PegIntron Preparation and Injection Easiness) Using a Patient Questionnaire Answered at 1 Month and 3 Months</measure>
    <time_frame>The patient was instructed to answer and return by mail the first self-questionnaire after 1 month of treatment and the second one after 3 months of treatment.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patient satisfaction for each item on the questionnaires was rated on a scale from 0 (not satisfied) to 7 (very satisfied).</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1995</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>Patients with chronic hepatitis C</arm_group_label>
    <description>Adult patients with chronic hepatitis C treated with PegIntron pen/Rebetol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Peginterferon alfa-2b (SCH 54031)</intervention_name>
    <description>Peginterferon alfa-2b will be administered according to the products' labeling.</description>
    <arm_group_label>Patients with chronic hepatitis C</arm_group_label>
    <other_name>PegIntron</other_name>
    <other_name>PegPen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin (SCH 18908)</intervention_name>
    <description>Ribavirin will be administered according to the products' labeling.</description>
    <arm_group_label>Patients with chronic hepatitis C</arm_group_label>
    <other_name>Rebetol</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with chronic hepatitis C treated with PegIntron pen/Rebetol at sites in
        France.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients with hepatitis C

        Exclusion Criteria:

          -  According to the products' labeling.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <verification_date>April 2015</verification_date>
  <lastchanged_date>April 7, 2015</lastchanged_date>
  <firstreceived_date>July 30, 2008</firstreceived_date>
  <firstreceived_results_date>June 18, 2009</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results are available for this study                                           -->
</clinical_study>
